THE FUSE

In July 2026, the FDA approved centanafadine, sold as Simtriyo, for ADHD. The trade coverage converged on two claims: that it's a first-in-class "triple reuptake inhibitor," and that it offers stimulant-like benefit with better tolerability. I treat ADHD and study its medications, I read all seven trial publications, and both claims survive only with significant fine print. That fine print is a useful case study in how to read any new drug launch, so let's walk through it together.